Beyond the Limit: MYC Mediates Tumor Immune Escape
Open Access
- 29 June 2025
- journal article
- review article
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (7) , 978
Abstract
MYC is an aberrantly regulated transcription factor implicated in approximately 70% of human tumors, where it extensively modulates signaling pathways associated with cancer progression. Inactivating MYC has been shown to inhibit tumor growth and even induce sustained tumor regression across various cancer types, a phenomenon referred to as oncogene addiction. However, in vitro studies reveal that the knockout or knockdown of MYC in numerous tumor cell lines does not necessarily result in cell death, despite these tumors exhibiting MYC addiction in vivo. This discrepancy suggests that the unique tumor microenvironment in vivo may play a critical role in facilitating MYC addiction in cancer cells. MYC is also widely acknowledged for its role in mediating the immune evasion of tumor cells. Nevertheless, due to the extensive regulation of cellular gene expression by MYC and the incomplete understanding of the mechanisms underlying tumor immune escape, the precise pathways through which MYC influences tumor immune evasion remain inadequately elucidated. Recent years have seen the identification of novel tumor immune escape mechanisms, some of which have been demonstrated to be directly or indirectly regulated by MYC. For instance, MYC may contribute to immune evasion by modulating the expression of argininosuccinate synthetase 1 (ASS1), a key enzyme involved in arginine biosynthesis. Herein, in this study, we explore some novel potential mechanisms through which MYC facilitates the immune evasion of tumor cells, alongside a combined therapeutic approach targeting MYC and employing immunotherapy based on this mechanism. Furthermore, we suggest that targeting proteins interacting with MYC to modulate its expression and function may serve as an alternative strategy to direct MYC targeting, thereby expediting the clinical translation of combination therapies.Keywords
Funding Information
- Key/Major Project of Jianhu Clinical College of Jiangsu Vocational College of Medicine (20229JH03, 202490202, 82373160)
- National Natural Science Foundation of China (20229JH03, 202490202, 82373160)
This publication has 138 references indexed in Scilit:
- Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III studyAnnals of Oncology, 2022
- A chemical conjugation of JQ‐1 and a TLR7 agonist induces tumoricidal effects in a murine model of melanoma via enhanced immunomodulationInternational Journal of Cancer, 2020
- Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance ImmunotherapyCancer Cell, 2019
- SOX4 is activated by C-MYC in prostate cancerMedical Oncology, 2019
- Survival of the fittest: how myeloid-derived suppressor cells survive in the inhospitable tumor microenvironmentCancer Immunology, Immunotherapy, 2019
- MYC Interacts with the G9a Histone Methyltransferase to Drive Transcriptional Repression and TumorigenesisCancer Cell, 2018
- Infiltrating neutrophils promote renal cell carcinoma (RCC) proliferation via modulating androgen receptor (AR) → c-Myc signalsCancer Letters, 2015
- Pharmacophore identification of c-Myc inhibitor 10074-G5Bioorganic & Medicinal Chemistry Letters, 2013
- Molecular profiling reveals frequent gain of MYCN and anaplasia‐specific loss of 4q and 14q in wilms tumorGenes, Chromosomes and Cancer, 2011
- Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc–Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in miceCancer Chemotherapy and Pharmacology, 2008